NEWS RELEASE

FOR IMMEDIATE RELEASE

Media Contact: Linda Welter Cohen
lcohen@calibergroup.com
520-547-3440

CRITICAL PATH INSTITUTE NAMES MARTHA BRUMFIELD CEO

TUCSON, Ariz. (Feb. 21, 2013) – The Board of Directors of the Critical Path Institute (C-Path) announced today that Martha Brumfield, Ph.D., has been named interim president and chief executive officer of the organization. Brumfield, C-Path's former director of International & Regulatory Programs, takes over immediately for Carolyn Compton, M.D., Ph.D., who will be assuming a new position at Arizona State University (ASU).

"Martha Brumfield brings world-class leadership and experience from her career in the dynamic world of bio-pharma, having successfully led global organizations, both large and small, through the complex arena of medical product approval and post-marketing safety evaluation," said Peter B. Corr, Ph.D., chairman of the C-Path board of directors. "Martha will be instrumental in helping the institute operate effectively in today's biomedical research and regulatory environment by bringing all stakeholders together to achieve a highly improved drug development and approval process, benefiting patients worldwide."

As interim president and CEO, Brumfield will help C-Path continue its mission to expand novel tools and methodologies that will accelerate the development and review of medical products," said Corr.

"During my time at C-Path, I have been impressed by the depth of scientific talent, the integrity and dedication of the staff and our partners and supporters," Brumfield said. "I look forward to achieving successes together and leveraging the strengths and mission of C-Path to advance regulatory science for the good of providers and patients."

Dr. Carolyn Compton, a professor at ASU, will now devote her full-time efforts to the National Biomarkers Development Alliance, a unique biomarker initiative that is headquartered at ASU. Dr. Compton, who has a lifelong passion for cancer research with a focus on biomarkers and biospecimans, helped plan the initiative along with the founding partners, ASU, C-Path and the International Genomic Consortium. Additionally, she is the chair of the American Joint Committee on Cancer and an executive committee member of the Commission on Cancer of the American College of Surgeons. Prior to C-Path, Dr. Compton held leadership positions at the National Cancer Institute, the College of American Pathologists, and was a professor of Pathology at Harvard Medical School.

"Carolyn has been a key participant in Arizona's progression to become a leader in biomarker development and regulatory pathways to approval," said Jeff Jacob, vice chairman of the C-Path board of directors. "She created and led strong, productive relationships with Arizona stakeholders dedicated to developing new biomarker pathway initiatives. I'm fully confident she will expand those relationships in her role with Arizona State University."

-more-

ABOUT THE CRITICAL PATH INSTITUTE

The Critical Path Institute (C-Path) is an independent, non-profit organization established in 2005 with public and private philanthropic support from the Arizona community, Science Foundation Arizona and the U.S. Food and Drug Administration (FDA). An international leader in forming collaborations, C-Path has established global, public-private partnerships that currently include more than 1,000 scientists from government regulatory agencies, academia, patient advocacy organizations and dozens of major pharmaceutical companies. C-Path is headquartered in Tucson, Ariz., and has an office in Rockville, MD. Visit www.c-path.org for more information.

###

Biography
Martha A. Brumfield, Ph.D.
President and CEO, Critical Path Institute

Martha Brumfield, Ph.D., was recently named the interim president and chief executive officer of the Critical Path Institute. In this role, Brumfield will lead the institute in its mission to foster development of new evaluation tools, which accelerate medical product approval. Brumfield assumes the role of CEO after most recently serving as Critical Path Institute's director of International & Regulatory Programs**.** In that position, she helped guide international program development and provided regulatory expertise to consortia.

She also leads her own consulting practice (Martha A. Brumfield LLC) focusing on concordance in global regulatory initiatives and regulatory science qualification programs. Other areas of focus in her practice include excellence in clinical trial conduct and pharmacovigilance, facilitation of scientific consortia and programs supporting patient access to medicines.

Brumfield brings 20 years of experience from Pfizer, Inc., most recently, as senior vice president of worldwide regulatory affairs and quality assurance. There, she led a global team that supported lifecycle pharmaceutical research, development and commercialization through creation and implementation of regulatory strategies and quality assurance oversight. Brumfield also played a key role in managing the broader company relationships with global regulators, trade associations, academics and others on regulatory policy issues. She served on corporate governance initiatives including the planning and implementation of mergers and acquisitions and led her departments through these periods of significant change.

She participates in an advisory capacity to the Harvard Global Health Institute's Multi-Regional Clinical Trial Center in developing a curriculum for potential Data and Safety Monitoring Board candidates from developing countries. She is also active with global nonprofits, including the Regulatory Harmonization Institute and GlobalMD, where she delivers educational workshops on regulatory and clinical trial topics in Asia. She has served on and contributed to the International Office of Medicine consensus committees, which were commissioned by U.S. FDA focusing on global regulatory systems.

Brumfield earned a B.S. and an M.S. in chemistry from Virginia Commonwealth University, a Ph.D. in organic chemistry from the University of Maryland and served as a post-doctoral fellow at the Rockefeller University.